|
Press Releases
|
TimTec Expands Partnership With Collaborative Drug Discovery Through Publishing Three Additional Libraries on CDD's Free Public Access Database
Last October, TimTec and Collaborative Drug Discovery (CDD) established a collaboration in which CDD's web-based data management system would host two TimTec Natural Products libraries on their free community Public Access site. Through this partnership, researchers would be able to register for a free account with CDD allowing them to chemically mine the contents of these TimTec compound libraries using CDD's powerful, intuitive web-based database software.
TimTec is now offering three more libraries on the CDD Public Access database:
The TimTec ActiTarg-K Kinase Modulators library contains over 6,000 compounds known to inhibit protein kinase activity:
The TimTec OGT Inhibitors Analogs library contains more than 300 compounds analogous to three known O-GlcNAc Transferase inhibiting molecules:
Finally, the TimTec resourceful Diversity Set is a general screening collection of drug-like compounds that present most diversified selection from TimTec stock. This screening library contains 10,000 of the most diverse compounds, all complying with the Lipinski Rule of Five:
TimTec's five databases join more than 25 other databases containing chemical and biological data hosted on CDD Public Access, including: 47,000 Ki values for 20,000 compounds against 699 GPCR targets from the NIMH Psychoactive Drug Screening Program at the University of North Carolina Over 15,000 compounds with Malaria assay data from 5 public data sources 48,818 compounds from the Distributed Drug Discovery (D3) at Indiana University – Purdue University Indianapolis (IUPUI) Almost 7,500 compounds with Tuberculosis antibacterial and cell viability information from 4 public data sets and growing thanks to their collaboration with the Bill & Melinda Gates Foundation
About TimTec, LLC. TimTec LLC. - http://www.timtec.net - is a privately held company located in Newark Delaware, USA. It was founded in 1995 and began its work in the areas of acquisition and distribution of synthetic organic and natural compounds, custom synthesis, and laboratory equipment to become a full service partner for drug discovery. TimTec has established a global network of thousands of scientists from research centers around the world. The company has developed strong in-house expertise assembling general and targeted library collections for variety of research purposes. International customers include major pharmaceutical, biotech, agricultural, and educational companies and institutions, which use TimTec products for research and development programs. For more information on TimTec library collections, please contact: Kay Denisova Business Development TimTec LLC Harmony Business Park Building 301-A Newark, DE 19711 Tel 302 292 8500 Fax 302 292 8520
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
http://www.timtec.net
About Collaborative Drug Discovery, Inc. Collaborative Drug Discovery, Inc. (CDD) - http://www.collaborativedrug.com - provides web-based software that organizes preclinical research data to help scientists advance new drug candidates more effectively. The CDD database enables scientists to “archive, mine, and collaborate”® around preclinical chemical and biological drug discovery data through a web-based interface. The software helps distributed research groups to safely store and intelligently analyze small molecule, enzyme, cell and animal bioactivity data accumulated from both low-throughput and high-throughput screens. Unique collaboration features and CDD’s community-oriented approach help unite globally dispersed humanitarian efforts against neglected infectious diseases. Similar collaborative strategies are also rapidly gaining prominence in the commercial arena. CDD offers its industrial-strength database software at a price affordable to academic laboratories, research foundations, and small companies.
For further information please contact:
Barry Bunin, PhD President & CEO Collaborative Drug Discovery (CDD) 1633 Bayshore Hwy, Suite 342 Burlingame, CA 94010
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
Drug Discovery News
-
Novel ‘Antisense’ Therapies Protect Primates from Lethal Ebola and Marburg Viruses
ScienceDaily (Aug. 23, 2010) — New studies show that treatments targeting specific viral genes protected monkeys infected with deadly Ebola or Marburg viruses. Furthermore, the animals were protected even when therapeutics were administered one hour after exposure — suggesting the approach holds promise for treating accidental infections in laboratory or hospital settings. See Also: Health [...]
-
Molecular Target for Screening: G-Protein-Coupled Receptors
Newark, DE. August, 2010 – Press Release – TimTec, LLC. – Molecular Target for Screening: G-Protein-Coupled Receptors, ActiTarg-G G-Protein-Coupled Receptors are the largest gene families in the human genome and, rightfully so, have become the leading molecular target in 2008. In 2009 SBS April meeting in Lille, France, followed-up with screening trends report stating that [...]
-
Actelion obtains option to acquire privately-held Trophos
Late-stage Phase III compound in Amyotrophic Lateral Sclerosis to report data in late 2011 – Novel therapeutic approach to be further explored in drug discovery collaboration ALLSCHWIL, SWITZERLAND and MARSEILLE, FRANCE – 20 July 2010 – Actelion Ltd (SIX: ATLN) and privately-held Trophos SA announced today that they have entered into a binding agreement whereby [...]
-
Screen for molecules that inhibit formation of A-beta oligomers
Alzheimer’s disease (AD) is a devastating neurological disorder characterized by the deposition of aggregated proteins in the brain in the form of extracellular beta-amyloid in senile plaques and intracellular tau in neurofibrillary tangles. A current approach towards treatment of Alzheimer’s disease is by using inhibitors of amyloid beta aggregation. Current screening protocols for inhibitors of [...]
-
Nine U.S. Health Research Centers to Receive $255 Million
Nine health research centers have received funds to develop ways to reduce the time it takes for clinical research to become treatments for patients. The funds were awarded as part of the Clinical and Translational Science Awards (CTSA) program which is led by the National Center for Research Resources (NCRR), part of the National Institutes [...]
-
BioFocus and University of Bristol enter drug discovery collaboration in chronic pain
Saffron Walden and Bristol, UK; 16 July 2010 – BioFocus and the University of Bristol today announced a new drug discovery collaboration aimed at developing treatments for chronic pain associated with diabetes (diabetic neuropathic pain). BioFocus will provide hit-to-lead and lead optimization services for a Wellcome Trust funded program at the University of Bristol. Total [...]
-
NIH Prolongs Compound-Management Arrangement with Galapagos Until End of 2012
NIH has extended its agreement with Galapagos’ service division, BioFocus, for the operation of the Molecular Libraries Small Molecule Repository (MLSMR) through December 2012. Galapagos will thus be eligible to receive up to $8.6 million over the course of the two-year extension. The NIH MLSMR collects samples for high-throughput biological screening and distributes them to [...]
-
Aquapharm and AMRI Enter into a Novel Marine Chemistry Collaboration
Aquapharm Biodiscovery, a leading marine biotechnology company, announced today it has signed a research agreement with Albany Molecular Research to identify novel drug-like compounds and scaffolds with anti-microbial and anti-inflammatory activity from Aquapharm’s marine natural products library derived from its extensive collection of marine micro-organisms.Under the terms of this agreement, drawing on its substantial experience [...]
-
Volatile Organic Compounds (VOCs) on the Gulf Coastline
Resource: EPA – United States Environmental Protection Agency Volatile Organic Compounds (VOCs) on the Gulf Coastline EPA is analyzing air samples for volatile organic compounds (VOCs) – including specifically, benzene, ethylbenzene, toluene, and xylene. EPA is sampling for these pollutants because they are present in oil and because, at elevated concentrations, they may cause health [...]
-
The NIH Molecular Libraries Program: Identifying Chemical Probes for New Medicines
Alice McCarthy In 2003, several program leaders within the National Institutes of Health (NIH) recognized that the results from the recently completed Human Genome Project were a launching pad for further study. Now that scientists knew the genome, how could they determine gene function? In particular, how could scientists find specific biological pathways and targets that [...]
|
info@timtec.net Harmony Business Park Building 301-A Newark, DE 19711 Toll free 800-574-7391 T: 302-292-8500 F: 302-292-8520
|
|
|
Call toll free 1 800 574 7391
|